Dark

Check out our API

CYAD
Celyad Oncology SA
stock NASDAQ

Inactive

May 18, 2023

0.4700USD-11.103%(-0.0587)49,047

Pre-market

Dec 31, 1969 7:00:00 PM EST

0.00USD-100.000%(-0.53)0

After-hours

Dec 31, 1969 7:00:00 PM EST

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Jan 31, 2022

04:05PM EST Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the Company plans to participate virtually in the following conference in February 2022: GlobeNewswire Inc

Jan 11, 2022

06:58AM EST Wells Fargo Maintains Overweight on Celyad Oncology, Lowers Price Target to $11 Benzinga

Jan 10, 2022

01:40AM EST Celyad Oncology Provides 2022 View RTTNews

01:00AM EST Celyad Oncology Provides Outlook for 2022 GlobeNewswire Inc

Dec 31, 2021

01:00AM EST Information on the Total Number of Voting Rights and Shares GlobeNewswire Inc

Dec 22, 2021

01:00AM EST Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the Company plans to participate virtually in the following conference in January 2022: GlobeNewswire Inc

Dec 17, 2021

04:05PM EST Transparency notification received from Tolefi SA and related GlobeNewswire Inc

Dec 16, 2021

01:10AM EST Celyad Oncology Doses First Patient In KEYNOTE-B79 Phase 1b Trial RTTNews

01:00AM EST -- KEYNOTE-B79 Phase 1b trial will evaluate CYAD-101 and KEYTRUDA (pembrolizumab) in patients with microsatellite stable (MSS) metastatic colorectal cancer (mCRC) -- ASCO-GI conference abstract accepted that highlights KEYNOTE-B79 clinical trial design GlobeNewswire Inc

Dec 15, 2021

01:00AM EST Transparency notification received from Fortress Investment Group GlobeNewswire Inc

Dec 13, 2021

01:08PM EST Celyad Oncology Early Monday Highlighted Presentation Of Updates On Its Short Hairpin RNA-Based CAR T Programs At American Society Of Hematology Meeting: 'Data continues to support the versatile potential of non-gene edited shRNA technology with updates.. Benzinga

01:00AM EST -- Data continues to support the versatile potential of non-gene edited shRNA technology with updates from the CYAD-02 and CYAD-211 clinical programs -- Management to host conference call today December 13th at 2:30 p.m. CET / 8:30 a.m. EST GlobeNewswire Inc

Dec 8, 2021

04:05PM EST Celyad Oncology Announces Closing of $32.5 Million Private GlobeNewswire Inc

Dec 3, 2021

02:32PM EST Mid-Afternoon Market Update: DocuSign Drops Following Weak Revenue Forecast; Longeveron Shares Climb Benzinga

12:03PM EST Mid-Day Market Update: Nasdaq Dips Over 400 Points; Marvell Technology Shares Rise Following Upbeat Earnings Benzinga

10:56AM EST Shares of Celyad Oncology SA (CYAD) jumped over 35% on Friday morning after the clinical-stage biotechnology company said it raised $32.5 million in a private placement with Fortress Investment Group. RTTNews

10:15AM EST Mid-Morning Market Update: Markets Open Lower; Big Lots Issues Weak Profit Forecast Benzinga

01:30AM EST Celyad Oncology Announces $32.5 Million Private Placement with GlobeNewswire Inc

Nov 12, 2021

07:20AM EST Codiak Biosciences, Kymera Therapeutics, Adicet, Celldex, Alector, Achilles, Innate, Celyad, Ruby, Replimune, Nkarta, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14 Benzinga

07:20AM EST Codiak Biosciences, Kymera Therapeutics, Adicet, Celldex, Achilles, Innate, Celyad, Ruby, Replimune, Nkarta, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14 Benzinga

07:18AM EST Codiak Biosciences, Kymera Therapeutics, Adicet, Celldex, Celyad, Ruby, Replimune, Nkarta, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14 Benzinga

07:17AM EST Codiak Biosciences, Kymera Therapeutics, Adicet, Celldex, Celyad, Ruby, Replimune, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14 Benzinga

07:16AM EST Codiak Biosciences, Kymera Therapeutics, Adicet, Celldex, Celyad, Replimune, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14 Benzinga

07:15AM EST Codiak Biosciences, Kymera Therapeutics, Adicet, Celyad, Replimune, Ikena, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14 Benzinga

07:14AM EST Codiak Biosciences, Kymera Therapeutics, Adicet, Celyad, Replimune, Corvus, Harpoon, Scholar Rock, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14 Benzinga

07:12AM EST Codiak Biosciences, Kymera Therapeutics, Adicet, Celyad, Replimune, Corvus, Harpoon, MiNK, Bolt, Aravive, Oncorus, Editas, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14 Benzinga

07:10AM EST Codiak Biosciences, Kymera Therapeutics, Adicet, Celyad, Corvus, MiNK, Oncorus, Nektar Therapeutics, Compugen, Checkmake Pharma, Iovance, Sensei Highlight Data To Be Presented At Society For Immunotherapy Of Cancer's Meeting Nov. 12-14 Benzinga

07:00AM EST Celyad Oncology Presents Preclinical Data on Allogeneic CAR T GlobeNewswire Inc

Nov 10, 2021

05:30PM EST Celyad Oncology Reports Co. Had Cash And Cash Equivalents Of 6.1M Vs. 5.9M YoY Benzinga

Nov 2, 2021

03:00AM EDT Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the Company plans to participate virtually in the following conference in November 2021: GlobeNewswire Inc

Oct 29, 2021

04:05PM EDT Information on the Total Number of Voting Rights and Shares GlobeNewswire Inc

Oct 1, 2021

08:01AM EDT Celyad Oncology To Present New Data On Allogeneic CAR T Therapy Program At The Society For Immunotherapy Of Cancer Annual Meeting Nov. 12 Benzinga

08:00AM EDT Celyad Oncology to Present New Data on Allogeneic CAR T Therapy GlobeNewswire Inc

Sep 1, 2021

01:00AM EDT Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the Company plans to participate at the following conferences in September 2021: GlobeNewswire Inc

Aug 6, 2021

06:07AM EDT HC Wainwright & Co. Maintains Buy on Celyad Oncology, Lowers Price Target to $15 Benzinga

Aug 5, 2021

08:08AM EDT The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO Benzinga

Aug 4, 2021

04:01PM EDT Celyad Oncology H1 EPS (1.02) Up from Benzinga

04:01PM EDT Celyad Oncology Reports First Half 2021 Financial Results and GlobeNewswire Inc

07:52AM EDT The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings Benzinga

Aug 1, 2021

11:19AM EDT The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs Benzinga

Jul 30, 2021

01:00AM EDT Information on the Total Number of Voting Rights and Shares GlobeNewswire Inc

Jul 29, 2021

01:00AM EDT Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the Company will report first half 2021 financial and operating results on the evening of Wednesday, August 4, 2021. GlobeNewswire Inc

Jul 20, 2021

04:05PM EDT Celyad Oncology Presents Updates on Allogeneic CAR T Clinical Candidates and shRNA-based Preclinical Concepts at Research & Development Day Benzinga

04:01PM EDT Celyad Oncology Presents Updates on Allogeneic CAR T Clinical GlobeNewswire Inc

Jul 16, 2021

07:37AM EDT The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study Benzinga

Jul 15, 2021

08:08AM EDT The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs Benzinga

Jul 13, 2021

04:03PM EDT Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced it will host a Research & Development webinar on Tuesday, July 20th at 11:30 a.m. EDT. GlobeNewswire Inc

08:05AM EDT The Daily Biotech Pulse: Equillium Issues Positive Regulatory Update, Biogen In-Licenses Multiple Sclerosis Drug, Aridis Releases COVID-19 Antibody Cocktail Data Benzinga

Jul 9, 2021

07:36AM EDT The Daily Biotech Pulse: Lilly, Morphic's Positive Data At ECCO, Humanigen's COVID Treatment Gets Expedited Review In UK, TransCode IPO Benzinga

Jul 8, 2021

07:45AM EDT The Daily Biotech Pulse: Priority Review For Amgen's Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test Benzinga

Jul 7, 2021

04:01PM EDT Celyad Oncology to Participate at the William Blair Biotech Focus GlobeNewswire Inc

07:41AM EDT The Daily Biotech Pulse: Opiant Spikes On Data, OncoSec Rallies On Merck Collaboration, XBiotech Special Dividend Benzinga

Jun 30, 2021

07:29AM EDT The Daily Biotech Pulse: COVID Disappointments For Altimmune And Angion, Brickell Jumps On Hyperhidrosis Study Updates, 2 IPOs Benzinga

01:00AM EDT Information on the Total Number of Voting Rights and Shares GlobeNewswire Inc

Jun 24, 2021

08:12AM EDT The Daily Biotech Pulse: Lilly Spikes On Alzheimer's Drug Regulatory Filing Plan, Applied Genetics, Arcus Issue Data Readouts, Adcom Test Awaits Incyte, Monte Rosa Prices IPO Benzinga

Jun 11, 2021

03:32PM EDT Celyad Oncology Shares Spike To Session High, Sell Off And Mark New Lows Following US Patent & Trademark Office Abstract For Co.'s 'COMPOSITIONS AND METHODS FOR IMPROVING PERSISTENCE OF CELLS FOR ADOPTIVE TRANSFER' Benzinga

02:59AM EDT Celyad Oncology Presents Preliminary Data from Phase 1 IMMUNICY-1 GlobeNewswire Inc

May 31, 2021

01:00AM EDT Information on the Total Number of Voting Rights and Shares GlobeNewswire Inc

May 26, 2021

01:00AM EDT Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the company plans to participate at the following conferences in June 2021: GlobeNewswire Inc

May 19, 2021

01:00AM EDT Transparency notification received from Victory Capital Management GlobeNewswire Inc

May 13, 2021

08:10AM EDT The Daily Biotech Pulse: Merck Reports Positive Keytruda Data In Breast Cancer, Curis, Evoke Slump On Earnings, Qiagen's Rapid COVID-19 Antibody Test OK'ed For Emergency Use Benzinga

06:53AM EDT Celyad Oncology Stock Surges On Positive Data From Multiple Myeloma Cell Therapy Benzinga

May 12, 2021

04:12PM EDT Celyad Oncology To Present Data From Phase 1 IMMUNICY-1 Trial Of Non-Gene Edited Allogeneic CAR T Candidate CYAD-211 In Relapsed/Refractory Multiple Myeloma At The European Hematology Association Virtual Congress Benzinga

04:01PM EDT Celyad Oncology to Present Data from Phase 1 IMMUNICY-1 Trial of GlobeNewswire Inc

08:57AM EDT The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron Benzinga

May 10, 2021

06:12AM EDT HC Wainwright & Co. Maintains Buy on Celyad Oncology, Lowers Price Target to $17 Benzinga

May 7, 2021

07:40AM EDT The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs Benzinga

May 6, 2021

07:49AM EDT The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom Benzinga

May 5, 2021

07:43AM EDT The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues Benzinga

01:00AM EDT Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that it has received a transparency notification from Tolefi SA, dated 3 May 2021. GlobeNewswire Inc

May 4, 2021

08:10AM EDT The Daily Biotech Pulse: Vaxart Rebounds On Strong Vaccine Data, Pfizer's Beat-And-Raise Quarter, BioLineRx Data Benzinga

01:00AM EDT Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, announced that Tolefi SAs shares benefit from a double voting right as of May 3, 2021. As a result, the Companys total number of voting rights is now 17,373,181. GlobeNewswire Inc

Apr 30, 2021

01:00AM EDT Information on the Total Number of Voting Rights and Shares GlobeNewswire Inc

Apr 21, 2021

07:31AM EDT The Daily Biotech Pulse: Moderna To Supply Variant-Specific Vaccine To Israel, Roche's Diagnostics Business Comes to Rescue Benzinga

Apr 19, 2021

01:13AM EDT Celyad Oncology Appoints Charles Morris As Chief Medical Officer RTTNews

01:00AM EDT Celyad Oncology Appoints Dr. Charles Morris as Chief Medical Officer GlobeNewswire Inc

Apr 15, 2021

07:49AM EDT The Daily Biotech Pulse: Merck Shelves 2 COVID-19 Studies, Bristol-Myers Squibb Gets European Regulatory Nod, InspireMD's Reverse Split Benzinga

Apr 14, 2021

07:51AM EDT The Daily Biotech Pulse: Novavax CFO Departs, Zai Lab Inks Cancer Drug Collaboration, FDA Nod For Gilead Benzinga

Apr 1, 2021

01:00AM EDT Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the company plans to participate at the following conferences in April 2021: GlobeNewswire Inc

Mar 31, 2021

01:00AM EDT Information on the Total Number of Voting Rights and Shares GlobeNewswire Inc

Mar 26, 2021

12:01PM EDT JonesTrading Downgrades Celyad Oncology to Hold Benzinga

Mar 24, 2021

04:03PM EDT Celyad Oncology Reports FY20 EPS (1.23) Up From Benzinga

04:01PM EDT Celyad Oncology Reports Full Year 2020 Financial Results and GlobeNewswire Inc

04:29AM EDT Earnings Scheduled For March 24, 2021 Benzinga

Mar 18, 2021

02:00AM EDT Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the Company will report full year 2020 financial and operating results on the evening of Wednesday, March 24th. GlobeNewswire Inc

Mar 1, 2021

04:01PM EST Mont-Saint-Guibert, Belgium Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the company plans to participate at the following virtual investor conferences in March 2021: GlobeNewswire Inc

Feb 2, 2021

01:00AM EST Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the company plans to participate at the following conferences in February 2021: GlobeNewswire Inc

Jan 20, 2021

04:05PM EST Information on the Total Number of Voting Rights and Shares GlobeNewswire Inc

Jan 18, 2021

01:08AM EST Celyad Oncology Presents Data Update From Phase 1 AlloSHRINK Trial For CYAD-101 In MCRC At ASCO-GI Symposium RTTNews

01:00AM EST Celyad Oncology Presents Data Update from Phase 1 alloSHRINK Trial GlobeNewswire Inc

Jan 11, 2021

04:01PM EST Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that Marina Udier, Ph.D., has been appointed to its Board of Directors. GlobeNewswire Inc

Jan 7, 2021

01:21AM EST Celyad Oncology Enters Committed Equity Purchase Agreement For Up To $40 Mln With Lincoln Park Capital Fund RTTNews

01:00AM EST Celyad Oncology Announces Equity Purchase Agreement for up to $40 GlobeNewswire Inc

Jan 5, 2021

01:00AM EST Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the company plans to participate at the following conferences in January 2021: GlobeNewswire Inc

Dec 29, 2020

02:26PM EST Mid-Morning Market Update: Markets Mixed; House Passes $2,000 Direct Payments Benzinga

Dec 15, 2020

04:02PM EST Celyad Oncology Successfully Doses First Patient in Expansion Cohort of the CYAD-101 Phase 1 alloSHRINK Trial for mCRC Benzinga

04:01PM EST -- Preliminary data from the expansion cohort are expected during first half 2021 GlobeNewswire Inc

Dec 8, 2020

06:11AM EST HC Wainwright & Co. Maintains Buy on Celyad Oncology, Lowers Price Target to $18 Benzinga

Dec 7, 2020

02:05AM EST Celyad Oncology SA (CYAD), a clinical-stage biotechnology company focused on chimeric antigen receptor T cell or CAR T therapies for cancer, issued Monday updates on allogeneic and autologous CAR T Programs. RTTNews

01:13AM EST Celyad Oncology Says Disappointed By Latest Update From Phase 1 THINK Trial For CYAD-01 RTTNews

01:00AM EST Celyad Oncology Provides Updates on Allogeneic and Autologous CAR GlobeNewswire Inc

Dec 4, 2020

01:00AM EST -- Preliminary data from the Phase 1 trial are expected first half 2021 -- Additional 3.4 million in non-dilutive funding from SPW-Recherche of the Walloon Region to support advancement of CYAD-211 GlobeNewswire Inc

Dec 1, 2020

04:01PM EST Celyad Oncology to Participate in a Fireside Chat at the JMP GlobeNewswire Inc

Nov 29, 2020

08:59AM EST The Week Ahead In Biotech: Hematology Conference Gets Underway, Vanda And BioCryst Await FDA Decisions Benzinga

Nov 10, 2020

04:01PM EST Celyad Oncology Announces Third Quarter 2020 Financial Results and GlobeNewswire Inc

Nov 4, 2020

04:01PM EST -- Three accepted abstracts will be presented virtually in a pre-recorded poster session GlobeNewswire Inc

Nov 2, 2020

04:01PM EST Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the company plans to participate at the following conferences in November 2020: GlobeNewswire Inc

Sep 29, 2020

05:33AM EDT Celyad Oncology Announced Clinical Trial Collaboration to Evaluate CYAD-101 with Merck's KEYTRUDA in Patients with Microsatellite Stable mCRC Benzinga

01:38AM EDT Celyad Oncology SA (CYAD) said that it has reached a clinical trial collaboration with Merck & Co. Inc. (MRK) to evaluate CYAD-101 with KEYTRUDA in patients with microsatellite stable refractory metastatic colorectal cancer. RTTNews

01:03AM EDT Celyad Oncology Enters Clinical Trial Collaboration With Merck RTTNews

01:00AM EDT Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, announced today that the Company has entered into a clinical trial collaboration with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ., USA, through a subsidiary. GlobeNewswire Inc

Sep 23, 2020

04:01PM EDT Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that Filippo Petti, Chief Executive Officer, will participate in a fireside chat at the virtual Jefferies Cell Therapy Summit on Monday, October 5, 2020, at 11:00 a.m. EDT. GlobeNewswire Inc

Sep 22, 2020

04:01PM EDT Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced it will host a Research & Development webinar on Tuesday, September 29th at 11:00 a.m. EDT. GlobeNewswire Inc

Sep 14, 2020

01:00AM EDT Celyad Oncology Establishes At-the-Market Facility GlobeNewswire Inc

Aug 28, 2020

04:07PM EDT Celyad Oncology Files For Mixed Shelf Of Up To $250M Benzinga

Aug 26, 2020

01:00AM EDT Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the company plans to participate at the following conferences in September 2020: GlobeNewswire Inc

Aug 3, 2020

01:00AM EDT Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the Company will report first half 2020 financial and operating results on the evening of Thursday, August 6, 2020. GlobeNewswire Inc

Jul 15, 2020

04:49AM EDT 55 Biggest Movers From Yesterday Benzinga

Jul 14, 2020

10:15AM EDT Shares of Celyad Oncology SA (CYAD) are currently gaining nearly 14% on Tuesday morning. On the other day, the clinical-stage biotechnology company said its Investigational New Drug application for CYAD-211, its first non-gene edited allogeneic CAR T Therapy, received clearance from the US FDA. RTTNews

05:25AM EDT Celyad Oncology Announces FDA Clearance of IND Application for CYAD-211, First shRNA-based, Non-Gene Edited Allogeneic CAR T Therapy Benzinga

01:00AM EDT -- Phase 1 clinical trial evaluating the off-the-shelf anti-BCMA CAR T candidate CYAD-211 for the treatment of relapsed/refractory multiple myeloma (r/r MM) expected to begin by year-end 2020 -- CYAD-211 represents the companys first allogeneic CAR T clinical candidate using shRNA technology GlobeNewswire Inc

Share